茶山 弘美HIROMI CHAYAMA

Last Updated :2020/09/10

所属・職名
大学院医系科学研究科(医) 准教授
メールアドレス
habehiroshima-u.ac.jp

基本情報

学位

  • 博士(医学) (広島大学)

研究分野

  • 工学 / プロセス・化学工学 / 生物機能・バイオプロセス
  • 医歯薬学 / 内科系臨床医学 / 消化器内科学

教育活動

授業担当

  1. 2020年, 博士課程・博士課程後期, セメスター(前期), スタートアップ生命科学コースワーク
  2. 2020年, 博士課程・博士課程後期, セメスター(後期), スタートアップ生命科学コースワーク
  3. 2020年, 博士課程・博士課程後期, セメスター(前期), スタートアップ生命科学コースワーク
  4. 2020年, 博士課程・博士課程後期, セメスター(前期), スタートアップ生命科学コースワーク
  5. 2020年, 博士課程・博士課程後期, セメスター(前期), スタートアップ生命科学コースワーク
  6. 2020年, 博士課程・博士課程後期, セメスター(後期), アドバンスド生命科学コースワーク
  7. 2020年, 博士課程・博士課程後期, セメスター(後期), アドバンスド生命科学コースワーク
  8. 2020年, 博士課程・博士課程後期, セメスター(後期), アドバンスド生命科学コースワーク
  9. 2020年, 博士課程・博士課程後期, セメスター(後期), アドバンスド生命科学コースワーク
  10. 2020年, 修士課程・博士課程前期, 1ターム, スタートアップ生命科学コースワーク
  11. 2020年, 修士課程・博士課程前期, 3ターム, スタートアップ生命科学コースワーク
  12. 2020年, 博士課程・博士課程後期, 3ターム, アドバンスド生命科学コースワーク

研究活動

学術論文(★は代表的な論文)

  1. Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib., Ther Adv Med Oncol.
  2. Signal activation of hepatitis B virus-related hepatocarcinogenesis by upregulation of SUV39h1., J Infect Dis.
  3. Comparative study on the replication of HCV1b genome between wild-type and cell culture-adaptive mutant in regard to sensitivities against anti-HCV drugs., Microbiol Immunol., 64巻, 4号, pp. 296-303
  4. Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy., J Med Virol., 92巻, pp. 210-218
  5. Regulation of the Hepatitis B virus replication and gene expression by the multi-functional protein TARDBP, SCIENTIFIC REPORTS, 9巻, 20190611
  6. Comparison of intracellular responses between HBV genotype A and C infection in human hepatocyte chimeric mice, JOURNAL OF GASTROENTEROLOGY, 54巻, 7号, pp. 650-659, 201907
  7. Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice, JOURNAL OF GENERAL VIROLOGY, 100巻, 7号, pp. 1123-1131, 201907
  8. Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy, JOURNAL OF GASTROENTEROLOGY, 53巻, 1号, pp. 107-118, JAN 2018
  9. Involvement of Porphyromonas gingivalis in the progression of non-alcoholic fatty liver disease, JOURNAL OF GASTROENTEROLOGY, 53巻, 2号, pp. 269-280, FEB 2018
  10. Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 500巻, 2号, pp. 152-157, JUN 2 2018
  11. Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure, JOURNAL OF GENERAL VIROLOGY, 99巻, 8号, pp. 1058-1065, AUG 2018
  12. CTL-associated and NK cell-associated immune responses induce different HBV DNA reduction patterns in chronic hepatitis B patients, JOURNAL OF VIRAL HEPATITIS, 25巻, 12号, pp. 1555-1564, 201812
  13. Endoplasmic reticulum-mediated induction of interleukin-8 occurs by hepatitis B virus infection and contributes to suppression of interferon responsiveness in human hepatocytes, VIROLOGY, 525巻, pp. 48-61, 201812
  14. The association between serum cytokine and chemokine levels and antiviral response by entecavir treatment in chronic hepatitis B patients, ANTIVIRAL THERAPY, 23巻, 3号, pp. 239-248, 2018
  15. Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients: a pilot study, ANTIVIRAL THERAPY, 23巻, 8号, pp. 639-646, 2018
  16. Interferon alpha treatment stimulates interferon gamma expression in type I NKT cells and enhances their antiviral effect against hepatitis C virus, PLOS ONE, 12巻, 3号, MAR 2 2017
  17. Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61巻, 6号, JUN 2017
  18. Usefulness of humanized cDNA-uPA/SCID mice for the study of hepatitis B virus and hepatitis C virus virology, JOURNAL OF GENERAL VIROLOGY, 98巻, 5号, pp. 1040-1047, MAY 2017
  19. Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61巻, 9号, SEP 2017
  20. Effect of tenofovir disoproxil fumarate on drug-resistant HBV clones, JOURNAL OF INFECTION, 72巻, 1号, pp. 91-102, JAN 2016
  21. Elimination of HCV via a non-ISG-mediated mechanism by vaniprevir and BMS-788329 combination therapy in human hepatocyte chimeric mice, VIRUS RESEARCH, 213巻, pp. 62-68, FEB 2 2016
  22. Antiviral effects of anti-HBs immunoglobulin and vaccine on HBs antigen seroclearance for chronic hepatitis B infection, JOURNAL OF GASTROENTEROLOGY, 51巻, 11号, pp. 1073-1080, NOV 2016
  23. Highly multiplexed CRISPR-Cas9-nuclease and Cas9-nickase vectors for inactivation of hepatitis B virus, GENES TO CELLS, 21巻, 11号, pp. 1253-1262, NOV 2016
  24. Combination therapies with daclatasvir and asunaprevir on NS3-D168 mutated HCV in human hepatocyte chimeric mice, ANTIVIRAL THERAPY, 21巻, 4号, pp. 307-315, 2016
  25. Protease Inhibitor Resistance Remains Even After Mutant Strains Become Undetectable by Deep Sequencing, JOURNAL OF INFECTIOUS DISEASES, 214巻, 11号, pp. 1687-1694, DEC 1 2016
  26. Differences in serum microRNA profiles in hepatitis B and C virus infection, JOURNAL OF INFECTION, 70巻, 3号, pp. 273-287, MAR 2015
  27. The effects of bisphosphonate zoledronic acid in hepatocellular carcinoma, depending on mevalonate pathway, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 30巻, 3号, pp. 619-627, MAR 2015
  28. Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1, JOURNAL OF VIRAL HEPATITIS, 22巻, 2号, pp. 158-165, FEB 2015
  29. Ribavirin dose reduction during telaprevir/ribavirin/peg-interferon therapy overcomes the effect of the ITPA gene polymorphism, JOURNAL OF VIRAL HEPATITIS, 22巻, 2号, pp. 166-174, FEB 2015
  30. Novel Robust in Vitro Hepatitis B Virus Infection Model Using Fresh Human Hepatocytes Isolated from Humanized Mice, AMERICAN JOURNAL OF PATHOLOGY, 185巻, 5号, pp. 1275-1285, MAY 2015
  31. Rapid, Sensitive, and Accurate Evaluation of Drug Resistant Mutant (NS5A-Y93H) Strain Frequency in Genotype 1b HCV by Invader Assay, PLOS ONE, 10巻, 6号, JUN 17 2015
  32. On-treatment low serum HBV RNA level predicts initial virological response in chronic hepatitis B patients receiving nucleoside analogue therapy, ANTIVIRAL THERAPY, 20巻, 4号, pp. 369-375, 2015
  33. Association between variants in the interferon lambda 4 locus and substitutions in the hepatitis C virus non-structural protein 5A, JOURNAL OF HEPATOLOGY, 63巻, 3号, pp. 554-563, SEP 2015
  34. Aryl hydrocarbon receptor plays protective roles in ConA-induced hepatic injury by both suppressing IFN- expression and inducing IL-22, INTERNATIONAL IMMUNOLOGY, 26巻, 3号, pp. 129-137, MAR 2014
  35. Ultra deep sequencing study of HCV genotype 1 in chronic hepatitis patients treated with daclatasvir, peg-interferon and ribavirin, Antimicrob Agents Chemother, 20140101
  36. Ultradeep Sequencing Study of Chronic Hepatitis C Virus Genotype 1 Infection in Patients Treated with Daclatasvir, Peginterferon, and Ribavirin, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 58巻, 4号, pp. 2105-2112, APR 2014
  37. Aryl hydrocarbon receptor protects against bacterial infection by promoting macrophage survival and reactive oxygen species production, INTERNATIONAL IMMUNOLOGY, 26巻, 4号, pp. 209-220, APR 2014
  38. Human microRNA hsa-miR-1231 suppresses hepatitis B virus replication by targeting core mRNA, JOURNAL OF VIRAL HEPATITIS, 21巻, 9号, pp. E89-E97, SEP 2014
  39. IFNL4/IL-28B haplotype structure and its impact on susceptibility to hepatitis C virus and treatment response in the Japanese population, JOURNAL OF GENERAL VIROLOGY, 95巻, pp. 1297-1306, JUN 2014
  40. New Insight Into the Enhanced Effect of Pegylated Interferon-alpha, HEPATOLOGY, 60巻, 4号, pp. 1435-1437, OCT 2014
  41. Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C, JOURNAL OF GASTROENTEROLOGY, 49巻, 12号, pp. 1548-1556, DEC 2014
  42. Single-nucleotide polymorphisms in GALNT8 are associated with the response to interferon therapy for chronic hepatitis C, JOURNAL OF GENERAL VIROLOGY, 94巻, pp. 81-89, JAN 2013
  43. Circulating microRNA-22 correlates with microRNA-122 and represents viral replication and liver injury in patients with chronic hepatitis B, JOURNAL OF MEDICAL VIROLOGY, 85巻, 5号, pp. 789-798, MAY 2013
  44. A genome-wide association study of HCV-induced liver cirrhosis in the Japanese population identifies novel susceptibility loci at the MHC region, JOURNAL OF HEPATOLOGY, 58巻, 5号, pp. 875-882, MAY 2013
  45. Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice, GUT, 62巻, 7号, pp. 1055-1061, JUL 2013
  46. A Translational Study of Resistance Emergence Using Sequential Direct-Acting Antiviral Agents for Hepatitis C Using Ultra-Deep Sequencing, AMERICAN JOURNAL OF GASTROENTEROLOGY, 108巻, 9号, pp. 1464-1472, SEP 2013
  47. Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients, JOURNAL OF GASTROENTEROLOGY, 48巻, 10号, pp. 1188-1204, OCT 2013
  48. A novel TK-NOG based humanized mouse model for the study of HBV and HCV infections, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 441巻, 1号, pp. 230-235, NOV 8 2013
  49. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir., J Hepatol., 58巻, pp. 646-654, 20130501
  50. HLA-DQB1*03 Confers Susceptibility to Chronic Hepatitis C in Japanese: A Genome-Wide Association Study, PLoS One, 8巻, 12号, pp. e84226, 20131201
  51. Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C, J Gastroenterol, 20131201
  52. Identification of novel HCV deletion mutants in chronic hepatitis C patients, ANTIVIRAL THERAPY, 17巻, 8号, pp. 1551-1561, 2012
  53. Toward the Establishment of a Prediction System for the Personalized Treatment of Chronic Hepatitis C, JOURNAL OF INFECTIOUS DISEASES, 205巻, 2号, pp. 204-210, JAN 15 2012
  54. Serum PAI-1 is a novel predictor for response to pegylated interferon-a-2b plus ribavirin therapy in chronic hepatitis C virus infection, JOURNAL OF VIRAL HEPATITIS, 19巻, 2号, pp. E126-E133, FEB 2012
  55. Severe necroinflammatory reaction caused by natural killer cell-mediated Fas/Fas ligand interaction and dendritic cells in human hepatocyte chimeric mouse, HEPATOLOGY, 56巻, 2号, pp. 555-566, AUG 2012
  56. IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients, JOURNAL OF GASTROENTEROLOGY, 47巻, 7号, pp. 834-844, JUL 2012
  57. Hepatitis B Virus-Specific miRNAs and Argonaute2 Play a Role in the Viral Life Cycle, PLOS ONE, 7巻, 10号, OCT 16 2012
  58. Spinal astrocytes contribute to the circadian oscillation of glutamine synthase, cyclooxygenase-1 and clock genes in the lumbar spinal cord of mice, NEUROCHEMISTRY INTERNATIONAL, 60巻, 8号, pp. 817-826, JUN 2012
  59. Effects of hepatitis B virus infection on the interferon response in immunodeficient human hepatocyte chimeric mice., J Infect Dis., 204巻, pp. 224-228, 20110401
  60. Hepatitis C virus infection suppresses the interferon response in the liver of the human hepatocyte chimeric mouse., PLoS One., 6巻, pp. e23856, 20110801
  61. Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice., J Hepatol., 54巻, pp. 872-878, 20110501
  62. IL-28B predicts response to chronic hepatitis C therapy--fine-mapping and replication study in Asian populations., J Gen Virol., 92巻, pp. 1071-1081, 20110801
  63. ★, Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers., Nat Genet., 43巻, pp. 797-800, 20111001
  64. A genome-wide association study of chronic hepatitis B identified novel risk locus in a Japanese population., Hum Mol Genet., 20巻, pp. 3884-3892, 20110301
  65. Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b., J Hepatol., 54巻, pp. 408-414, 20110901
  66. Rapid emergence of telaprevir resistant hepatitis C virus strain from wildtype clone in vivo., Hepatology., 54巻, pp. 781-788, 20110901
  67. Impact of viral amino acid substitutions and host interleukin-28b polymorphism on replication and susceptibility to interferon of hepatitis C virus., Hepatology., 54巻, pp. 764-771, 20110201
  68. HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy., Gut., 60巻, pp. 261-267, 20110101
  69. Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b., J Med Virol., 83巻, pp. 981-988, 20110401
  70. A single nucleotide polymorphism in activated Cdc42 associated tyrosine kinase 1 influences the interferon therapy in hepatitis C patients., J Hepatol., 54巻, pp. 629-639, 20110101
  71. Animal model for study of human hepatitis viruses., J Gastroenterol Hepatol., 26巻, pp. 13-18, 20110701
  72. IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C., J Infect Dis., 204巻, pp. 84-93, 20110601
  73. Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy., J Med Virol., 83巻, pp. 1048-1057, 20110701
  74. ME3738 enhances the effect of interferon and inhibits hepatitis C virus replication both in vitro and in vivo., J Hepatol., 55巻, pp. 41596, 20110901
  75. Inverse association of IL28B genotype and liver mRNA expression of genes promoting or suppressing antiviral state., J Med Virol., 83巻, pp. 1597-1607, 20110601
  76. IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy., J Hepatol., 54巻, pp. 1094-1101, 20110501
  77. Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice, JOURNAL OF HEPATOLOGY, 54巻, 5号, pp. 872-878, MAY 2011
  78. Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b, JOURNAL OF HEPATOLOGY, 54巻, 3号, pp. 408-414, MAR 2011
  79. A single nucleotide polymorphism in activated cdc42 associated tyrosine kinase 1 influences the interferon therapy in hepatitis C patients, JOURNAL OF HEPATOLOGY, 54巻, 4号, pp. 629-639, APR 2011
  80. Rapid Emergence of Telaprevir Resistant Hepatitis C Virus Strain from Wildtype Clone In Vivo, HEPATOLOGY, 54巻, 3号, pp. 781-788, SEP 2011
  81. Prediction of Response to Peginterferon-Alfa-2b Plus Ribavirin Therapy in Japanese Patients Infected With Hepatitis C Virus Genotype 1b, JOURNAL OF MEDICAL VIROLOGY, 83巻, 6号, pp. 981-988, JUN 2011
  82. Common Genetic Polymorphism of ITPA Gene Affects Ribavirin-Induced Anemia and Effect of Peg-Interferon Plus Ribavirin Therapy, JOURNAL OF MEDICAL VIROLOGY, 83巻, 6号, pp. 1048-1057, JUN 2011
  83. IL-28B predicts response to chronic hepatitis C therapy - fine-mapping and replication study in Asian populations, JOURNAL OF GENERAL VIROLOGY, 92巻, pp. 1071-1081, MAY 2011
  84. IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy, JOURNAL OF HEPATOLOGY, 54巻, 6号, pp. 1094-1101, JUN 2011
  85. ME3738 enhances the effect of interferon and inhibits hepatitis C virus replication both in vitro and in vivo, JOURNAL OF HEPATOLOGY, 55巻, 1号, pp. 11-18, JUL 2011
  86. IL28B But Not ITPA Polymorphism Is Predictive of Response to Pegylated Interferon, Ribavirin, and Telaprevir Triple Therapy in Patients With Genotype 1 Hepatitis C, JOURNAL OF INFECTIOUS DISEASES, 204巻, 1号, pp. 84-93, JUL 1 2011
  87. Inverse Association of IL28B Genotype and Liver mRNA Expression of Genes Promoting or Suppressing Antiviral State, JOURNAL OF MEDICAL VIROLOGY, 83巻, 9号, pp. 1597-1607, SEP 2011
  88. Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers, NATURE GENETICS, 43巻, 8号, pp. 797-U108, AUG 2011
  89. Hepatitis C Virus Infection Suppresses the Interferon Response in the Liver of the Human Hepatocyte Chimeric Mouse, PLOS ONE, 6巻, 8号, AUG 23 2011
  90. Impact of Viral Amino Acid Substitutions and Host Interleukin-28B Polymorphism on Replication and Susceptibility to Interferon of Hepatitis C Virus, HEPATOLOGY, 54巻, 3号, pp. 764-771, SEP 2011
  91. A genome-wide association study of chronic hepatitis B identified novel risk locus in a Japanese population, HUMAN MOLECULAR GENETICS, 20巻, 19号, pp. 3884-3892, OCT 1 2011
  92. G to A hypermutation of TT virus., Virus Res., 149巻, pp. 211-216, 20100701
  93. HBx protein is indispensable for development of viraemia in human hepatocyte chimeric mice., J Gen Virol., 91巻, pp. 1854-1864, 20101001
  94. ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients., Gastroenterology., 139巻, pp. 1190-1197, 20100801
  95. Importance of serum concentration of adefovir for Lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B., Antimicrob Agents Chemother., 54巻, pp. 3205-3211, 20100401
  96. Amino acid substitutions in core and NS5A regions of the HCV genome can predict virological decrease with pegylated interferon plus ribavirin therapy., Antivir Ther., 15巻, pp. 1087-1097, 20100401
  97. Differential effects of interferon and lamivudine on serum HBV RNA inhibition in patients with chronic hepatitis B., Antivir Ther., 15巻, pp. 177-184, 20100901
  98. Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients., J Hepatol., 53巻, pp. 439-443, 20100501
  99. Differential effects of interferon and lamivudine on serum HBV RNA inhibition in patients with chronic hepatitis B, ANTIVIRAL THERAPY, 15巻, 2号, pp. 177-184, 2010
  100. G to A hypermutation of TT virus, VIRUS RESEARCH, 149巻, 2号, pp. 211-216, MAY 2010
  101. HBx protein is indispensable for development of viraemia in human hepatocyte chimeric mice, JOURNAL OF GENERAL VIROLOGY, 91巻, pp. 1854-1864, JUL 2010
  102. Importance of Serum Concentration of Adefovir for Lamivudine-Adefovir Combination Therapy in Patients with Lamivudine-Resistant Chronic Hepatitis B, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 54巻, 8号, pp. 3205-3211, AUG 2010
  103. Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients, JOURNAL OF HEPATOLOGY, 53巻, 3号, pp. 439-443, SEP 2010
  104. Amino acid substitutions in core and NS5A regions of the HCV genome can predict virological decrease with pegylated interferon plus ribavirin therapy, ANTIVIRAL THERAPY, 15巻, 8号, pp. 1087-1097, 2010
  105. A polymorphism in MAPKAPK3 affects response to interferon therapy for chronic hepatitis C., Gastroenterology., 136巻, pp. 1796-1805, 20090601
  106. G-to-A hypermutation in hepatitis B virus (HBV) and clinical course of patients with chronic HBV infection., J Infect Dis., 199巻, pp. 1599-1607, 20091201
  107. Absence of viral interference and different susceptibility to interferon between hepatitis B virus and hepatitis C virus in human hepatocyte chimeric mice., J Hepatol., 51巻, pp. 1046-1054, 20091201
  108. Effects of structural variations of APOBEC3A and APOBEC3B genes in chronic hepatitis B virus infection., Hepatol Res., 39巻, pp. 1159-1168, 20090901
  109. Establishment of an infectious genotype 1b hepatitis C virus clone in human hepatocyte chimeric mice., J Gen Virol., 89巻, pp. 2108-2113, 20080101
  110. Successful treatment of an entecavir-resistant hepatitis B virus variant., J Med Virol., 79巻, pp. 1811-1817, 20070201
  111. Dual effect of APOBEC3G on Hepatitis B virus., J Gen Virol., 88巻, pp. 432-440, 20070501
  112. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis C virus and its susceptibility to interferon., FEBS Lett., 581巻, pp. 1983-1987, 20070501
  113. Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine., Hepatology., 45巻, pp. 1179-1186, 20071101
  114. Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif., Antimicrob Agents Chemother., 50巻, pp. 3867-3874, 20061201
  115. Effects of sesamin and capsaicin on the mRNA expressions of delta6 and delta5 desaturases in rat primary cultured hepatocytes., Journal of nutritional science and vitaminology, 49巻, 6号, 2003
  116. Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif., Antimicrobial agents and chemotherapy, 50巻, 11号, 2006
  117. Dual effect of APOBEC3G on Hepatitis B virus., The Journal of general virology, 88巻, Pt 2号, 2007
  118. Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine., Hepatology (Baltimore, Md.), 45巻, 5号, 2007
  119. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis C virus and its susceptibility to interferon., FEBS letters, 581巻, 10号, 2007
  120. Successful treatment of an entecavir-resistant hepatitis B virus variant., Journal of medical virology, 79巻, 12号, 2007
  121. Establishment of an infectious genotype 1b hepatitis C virus clone in human hepatocyte chimeric mice., The Journal of general virology, 89巻, Pt 9号, 2008
  122. G-to-A hypermutation in hepatitis B virus (HBV) and clinical course of patients with chronic HBV infection., The Journal of infectious diseases, 199巻, 11号, 2009
  123. Absence of viral interference and different susceptibility to interferon between hepatitis B virus and hepatitis C virus in human hepatocyte chimeric mice., Journal of hepatology, 51巻, 6号, 2009
  124. G to A hypermutation of TT virus., Virus research, 149巻, 2号, 2010
  125. HBx protein is indispensable for development of viraemia in human hepatocyte chimeric mice., The Journal of general virology, 91巻, Pt 7号, 2010
  126. Importance of serum concentration of adefovir for Lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B., Antimicrobial agents and chemotherapy, 54巻, 8号, 2010
  127. Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice., Journal of hepatology, 54巻, 5号, 2011
  128. ME3738 enhances the effect of interferon and inhibits hepatitis C virus replication both in vitro and in vivo., Journal of hepatology, 55巻, 1号, 2011
  129. Amino acid substitutions in core and NS5A regions of the HCV genome can predict virological decrease with pegylated interferon plus ribavirin therapy., Antiviral therapy, 15巻, 8号, 2010
  130. Animal model for study of human hepatitis viruses., Journal of gastroenterology and hepatology, 26巻, 1号, 2011
  131. Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b., Journal of medical virology, 83巻, 6号, 2011
  132. Impact of viral amino acid substitutions and host interleukin-28b polymorphism on replication and susceptibility to interferon of hepatitis C virus., Hepatology (Baltimore, Md.), 54巻, 3号, 2011
  133. Rapid emergence of telaprevir resistant hepatitis C virus strain from wildtype clone in vivo., Hepatology (Baltimore, Md.), 54巻, 3号, 2011
  134. Effects of hepatitis B virus infection on the interferon response in immunodeficient human hepatocyte chimeric mice., The Journal of infectious diseases, 204巻, 2号, 2011
  135. Hepatitis C virus infection suppresses the interferon response in the liver of the human hepatocyte chimeric mouse., PloS one, 6巻, 8号, 2011
  136. Severe necroinflammatory reaction caused by natural killer cell-mediated Fas/Fas ligand interaction and dendritic cells in human hepatocyte chimeric mouse., Hepatology (Baltimore, Md.), 56巻, 2号, 2012
  137. IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients., Journal of gastroenterology, 47巻, 7号, 2012
  138. Spinal astrocytes contribute to the circadian oscillation of glutamine synthase, cyclooxygenase-1 and clock genes in the lumbar spinal cord of mice., Neurochemistry international, 60巻, 8号, 2012
  139. Identification of novel HCV deletion mutants in chronic hepatitis C patients., Antiviral therapy, 17巻, 8号, 2012
  140. Hepatitis B virus-specific miRNAs and Argonaute2 play a role in the viral life cycle., PloS one, 7巻, 10号, 2012
  141. Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice., Gut, 62巻, 7号, 2013
  142. Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients., Journal of gastroenterology, 48巻, 10号, 2013
  143. Circulating microRNA-22 correlates with microRNA-122 and represents viral replication and liver injury in patients with chronic hepatitis B., Journal of medical virology, 85巻, 5号, 2013
  144. A translational study of resistance emergence using sequential direct-acting antiviral agents for hepatitis C using ultra-deep sequencing., The American journal of gastroenterology, 108巻, 9号, 2013
  145. A novel TK-NOG based humanized mouse model for the study of HBV and HCV infections., Biochemical and biophysical research communications, 441巻, 1号, 2013
  146. Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C., Journal of gastroenterology, 49巻, 12号, 2014
  147. HLA-DQB1*03 confers susceptibility to chronic hepatitis C in Japanese: a genome-wide association study., PloS one, 8巻, 12号, 2013
  148. Ultradeep sequencing study of chronic hepatitis C virus genotype 1 infection in patients treated with daclatasvir, peginterferon, and ribavirin., Antimicrobial agents and chemotherapy, 58巻, 4号, 2014
  149. IFNL4/IL-28B haplotype structure and its impact on susceptibility to hepatitis C virus and treatment response in the Japanese population., The Journal of general virology, 95巻, Pt 6号, 2014
  150. New insight into the enhanced effect of pegylated interferon-α., Hepatology (Baltimore, Md.), 60巻, 4号, 2014
  151. Effects of bisphosphonate zoledronic acid in hepatocellular carcinoma, depending on mevalonate pathway., Journal of gastroenterology and hepatology, 30巻, 3号, 2015
  152. Differences in serum microRNA profiles in hepatitis B and C virus infection., The Journal of infection, 70巻, 3号, 2015
  153. Novel robust in vitro hepatitis B virus infection model using fresh human hepatocytes isolated from humanized mice., The American journal of pathology, 185巻, 5号, 2015
  154. Association between variants in the interferon lambda 4 locus and substitutions in the hepatitis C virus non-structural protein 5A., Journal of hepatology, 63巻, 3号, 2015
  155. Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy., Journal of medical virology, 87巻, 11号, 2015
  156. Rapid, Sensitive, and Accurate Evaluation of Drug Resistant Mutant (NS5A-Y93H) Strain Frequency in Genotype 1b HCV by Invader Assay., PloS one, 10巻, 6号, 2015
  157. Human Cytotoxic T Lymphocyte-Mediated Acute Liver Failure and Rescue by Immunoglobulin in Human Hepatocyte Transplant TK-NOG Mice., Journal of virology, 89巻, 19号, 2015
  158. Effect of tenofovir disoproxil fumarate on drug-resistant HBV clones., The Journal of infection, 72巻, 1号, 2016
  159. Combination therapies with daclatasvir and asunaprevir on NS3-D168 mutated HCV in human hepatocyte chimeric mice., Antiviral therapy, 21巻, 4号, 2016
  160. Elimination of HCV via a non-ISG-mediated mechanism by vaniprevir and BMS-788329 combination therapy in human hepatocyte chimeric mice., Virus research, 213巻, 2016
  161. Altered Serum Levels of Matrix Metalloproteinase-2, -9 in Response to Electroconvulsive Therapy for Mood Disorders., The international journal of neuropsychopharmacology, 19巻, 9号, 2016
  162. Antiviral effects of anti-HBs immunoglobulin and vaccine on HBs antigen seroclearance for chronic hepatitis B infection., Journal of gastroenterology, 51巻, 11号, 2016
  163. Pan-genotypic cell culture system for propagation of hepatitis C virus clinical isolates., Hepatology (Baltimore, Md.), 64巻, 4号, 2016
  164. Protease Inhibitor Resistance Remains Even After Mutant Strains Become Undetectable by Deep Sequencing., The Journal of infectious diseases, 214巻, 11号, 2016
  165. Usefulness of humanized cDNA-uPA/SCID mice for the study of hepatitis B virus and hepatitis C virus virology., The Journal of general virology, 98巻, 5号, 2017
  166. Circulating Tumor DNA Analysis for Liver Cancers and Its Usefulness as a Liquid Biopsy., Cellular and molecular gastroenterology and hepatology, 1巻, 5号, 2015
  167. Interferon alpha treatment stimulates interferon gamma expression in type I NKT cells and enhances their antiviral effect against hepatitis C virus., PloS one, 12巻, 3号, 2017
  168. Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus., Antimicrobial agents and chemotherapy, 61巻, 6号, 2017
  169. Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy., Journal of gastroenterology, 53巻, 1号, 2018
  170. Erratum to: Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy., Journal of gastroenterology, 53巻, 1号, 2018
  171. Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice., Antimicrobial agents and chemotherapy, 61巻, 9号, 2017
  172. Involvement of Porphyromonas gingivalis in the progression of non-alcoholic fatty liver disease., Journal of gastroenterology, 53巻, 2号, 2018
  173. The association between serum cytokine and chemokine levels and antiviral response by entecavir treatment in chronic hepatitis B patients., Antiviral therapy, 23巻, 3号, 2018
  174. Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice., Biochemical and biophysical research communications, 500巻, 2号, 2018
  175. Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients: a pilot study., Antiviral therapy, 2018
  176. Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure., The Journal of general virology, 99巻, 8号, 2018
  177. CTL-associated and NK cell-associated immune responses induce different HBV DNA reduction patterns in chronic hepatitis B patients., Journal of viral hepatitis, 2018

外部資金

競争的資金等の採択状況

  1. 民間からの助成金, IL28B 遺伝子多型の生物学的効果の機序解明に関する研究, 2011年
  2. 科学研究費助成事業(基盤研究(C)), ヒト肝細胞キメラマウスとバキュロウイルスを用いた遺伝病モデルの創生, 2014年, 2016年
  3. 科学研究費助成事業(若手研究(B)), ヒト肝細胞キメラマウスと次世代シーケンサーを用いた肝炎ウイルスゲノムの解析, 2012年, 2013年
  4. 科学研究費助成事業(若手研究(B)), IL-28BのSNPとHCV遺伝子に関する研究, 2010年, 2011年
  5. 平成30年度地球規模保健課題解決推進のための研究事業, 2018年, 2019年